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Abstract 
The existence of an acetyl group deficit at ≥90% 2oV
 max has proved controversial, with 
contradictory results likely relating to limitations in previous research.  The purpose of 
the present study was therefore to test whether or not the ‘acetyl group deficit’ occurs at 
the start of exercise at 90% 2oV
 max in a well controlled study.  Eight male participants 
(age: 33.6 ± 2.0 yrs; 2oV
 max: 3.60 ± 0.21 l.min-1) completed two exercise bouts at 90% 
2oV
 max for 3-min following either 30-min saline (control) or dichloroacetate (50 mg.kg-
1
bm) infusion, ending 15-min before exercise.  Muscle biopsies were obtained 
immediately before and following exercise while continuous non-invasive measures of 
pulmonary oxygen uptake and muscle deoxygenation were made.  Muscle pyruvate 
dehydrogenase activity was significantly higher prior to exercise following 
dichloroacetate infusion (control: 2.67 ± 0.98) vs dichloroacetate: 17.9 ± 1.1 mmol 
acetyl-CoA·min
-1.
mg
-1 
protein, P=0.01) and resulted in higher pre- and post-exercise 
muscle acetylcarnitine (pre ex control: 3.3 ± 0.95 vs pre-ex dichloroacetate: 8.0 ± 0.88 
vs post-ex control: 11.9 ± 1.1 vs post-ex dichloroacetate: 17.2 ± 1.1; mmol
.
kg
-1 
dm, 
P<0.05), yet substrate level phosphorylation (control: 125.0 ± 20 vs dichloroacetate: 
113.0 ± 13 mmol adenosine triphosphate
.
kg
-1
dm) and 2oV
  kinetics (
2Vo
 ), (control: 19.2 
± 2.2 vs dichloroacetate: 22.8 ± 2.5 s), were unaltered.  Additionally, dichloroacetate 
infusion blunted the slow component of 2oV
  & muscle deoxygenation and slowed 
muscle deoxygenation kinetics, possibly by enhancing oxygen delivery during exercise.  
These data support the hypothesis that the ‘acetyl group deficit’ does not occur at 
≥90% 2oV
 max. 
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Introduction 
The rise of [adenosine diphosphate] in the exercising muscle is a key stimulant of 
mitochondrial oxidative phosphorylation at the onset of exercise.  However, substrate 
level phosphorylation (phosphocreatine hydrolysis and lactate accumulation), which 
meets the shortfall of adenosine triphosphate resynthesis from oxidative phosphorylation 
at the onset of exercise, buffers the rise of [adenosine diphosphate] in the exercising 
muscle and thus, counter intuitively, prevents a more rapid activation of oxidative 
phosphorylation (Kindig, Howlett, Stary, Walsh, & Hogan, 2005).  In order to account for 
the relative stability of [adenosine diphosphate] in the face of large increases in oxidative 
phosphorylation during the rest-to-work transition, it has been suggested (Korzeniewski 
& Zoladz, 2004) that direct activation of enzymes in the oxidative respiratory chain 
(adenosine triphosphate supply pathways) is also required (Hochachka & Matheson, 
1992).  It was further demonstrated that enhanced activation of adenosine triphosphate 
supply pathways (e.g. by training or pharmacological intervention) reduced the 
adenosine diphosphate concentration, and thus phosphocreatine degradation & lactate 
accumulation, required to stimulate a given increase in oxygen consumption 
(Korzeniewski & Zoladz 2004).  Hence prior activation of key enzymes in the oxidative 
respiratory chain should speed muscle oxygen consumption kinetics and be mirrored by 
reductions in substrate level phosphorylation (Korzeniewski & Zoladz 2004).  
 
A number of studies have demonstrated that the pyruvate dehydrogenase complex is a 
key enzyme, which limits adenosine triphosphate supply pathways at the onset of at 
least during moderate intensity exercise, since activation of the pyruvate dehydrogenase 
complex via dichloroacetate infusion prior to exercise has repeatedly been shown to 
reduce reliance on non-oxidative adenosine triphosphate provision, at the onset of sub-
maximal intensity exercise (Durkot, De Garavilla, Caretti, & Francesconi, 1995; Timmons 
et al., 1996; Timmons, Poucher, Constantin-Teodosiu, Macdonald, & Greenhaff, 1997; 
Timmons, Gustafsson, Sundberg, Jansson, & Greenhaff, 1998a; Timmons et al., 1998b; 
Howlett, Heigenhauser, Hultman, Hollidge-Horvat, & Spriet, 1999; Parolin et al., 2000; 
Roberts, Loxham, Poucher, Constantin-Teodosiu, & Greenhaff, 2002; Howlett & Hogan, 
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2003).  The pyruvate dehydrogenase complex catalyses the irreversible conversion of 
pyruvate to acetyl-CoA, through which carbohydrates are committed to oxidative 
metabolism in the tricarboxylic acid cycle and electron transport chain. Intravenous 
infusion of dichloroacetate promotes dephosphorylation of the pyruvate dehydrogenase 
complex via inhibition of pyruvate dehydrogenase kinase, resulting in near maximal 
activation of the pyruvate dehydrogenase complex and a concomitant stockpiling of 
acetyl groups in resting muscle (Constantin-Teodosiu, Simpson, & Greenhaff, 1999).  
Hence, Greenhaff et al. (Greenhaff et al., 2002) coined the term “acetyl group deficit” to 
describe the lag in pyruvate dehydrogenase complex activation and thus acetyl-group 
delivery to the tricarboxylic acid cycle at the onset of exercise.  However, Roberts et al. 
(Roberts et al. 2002) suggested that the acetyl group deficit exists within only a limited 
range of exercise intensities (65%-90% 2oV
 max).  At higher exercise intensities (>90% 
2oV
 max), these authors suggested that pyruvate dehydrogenase complex flux and 
acetyl group availability would not limit tricarboxylic acid cycle flux due to rapid activation 
of the pyruvate dehydrogenase complex at the onset of muscle contraction, probably 
mediated via increased [Ca
2+
].  In contrast, during lower intensity exercise (<65% 
2oV
 max), the magnitude of metabolic inertia would be less, since the rate of adenosine 
triphosphate demand would be lower and therefore better matched by the existing rate 
of pyruvate dehydrogenase complex activation and flux at the onset of exercise.  
Nevertheless, the existence or otherwise of an ‘acetyl group deficit’ at exercise 
intensities ≥90% 2oV
 max remains controversial since the results of previous studies 
examining this issue have not been consistent.  This may in part be due to the variety of 
exercise modes and intensities employed; however, the collection of insufficient data 
and use of confounding methodologies in some studies have generated inconsistent 
conclusions regarding the acetyl group deficit. 
 
Previous research on this issue has shown that dichloroacetate infusion reduced both 
blood lactate accumulation and the absolute degradation of phosphocreatine (measured 
via 
31
P-MRS) during high intensity knee-extensor exercise (Rossiter et al., 2003), 
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although pulmonary 2oV
  kinetics were unaffected.  In addition, Timmons et al. 
(Timmons, Constantin-Teodosiu, Poucher, & Greenhaff, 2004) showed that 
phosphocreatine degradation was reduced during the first minute of intense tetanic 
contraction in canine skeletal muscle following dichloroacetate infusion.  In contrast, 
other studies (Bangsbo, Gibala, Krustrup, Gonzalez-Alonso, & Saltin, 2002; Savasi, 
Evans, Heigenhauser, & Spriet, 2002) found no effect of prior dichloroacetate infusion 
on non-oxidative adenosine triphosphate provision at the onset of cycle exercise at 90% 
2oV
 max and leg kicking at 110% of peak thigh 2oV max, respectively.  Furthermore, 
there was no effect of dichloroacetate infusion prior to cycle exercise at 80% 2oV
 peak 
on pulmonary oxygen uptake kinetics (Jones, Koppo, Wilkerson, Wilmshurst, & 
Campbell, 2004). 
 
These contradictory data likely relate to a number of differences between and limitations 
within some of the previous research.  The studies by Bangsbo et al. (Bangsbo et al. 
2002), Rossiter et al. (Rossiter et al. 2003) and Jones et al. (Jones et al. 2004) failed to 
make concurrent measurement of both acetyl group availability and pyruvate 
dehydrogenase complex activation status before and during exercise.  Accurate 
measures of both of these factors are necessary when evaluating the acetyl group deficit 
(Roberts et al. 2002; Roberts, Loxham, Poucher, Constantin-Teodosiu, & Greenhaff, 
2005).  In addition, Savasi et al. (Savasi et al. 2002) and Jones et al. (Jones et al. 2004) 
utilised intermittent exercise protocols, which are likely to blunt the effects of 
dichloroacetate infusion, since prior exercise causes activation of the pyruvate 
dehydrogenase complex.  Furthermore, it is not clear how well the data from different 
species, e.g. canine muscle, (Timmons et al. 2004), and small muscle mass exercise 
(Bangsbo et al. 2002; Rossiter et al. 2003) compare to upright large muscle mass 
exercise in humans.  Indeed determination of pulmonary 2oV
 kinetics in the latter study 
was limited by the relatively small amplitude of the response to exercise (~ 0.8 l
.
min
-1
) 
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In an attempt to resolve some of the present conflict, the purpose of the present study 
was therefore to determine whether the acetyl group deficit was evident at the start of 
exercise at 90% 2oV
 max. To achieve this, pyruvate dehydrogenase complex activation 
status, muscle acetylcarnitine and substrate level phosphorylation were measured from 
muscle samples extracted prior to and immediately following exercise with prior infusion 
of saline or dichloroacetate.  In a novel approach, these measures were taken in 
combination with continuous, non-invasive measurements of pulmonary oxygen uptake 
and muscle deoxygenation (via near infrared spectroscopy).  We hypothesised that 
activation of the pyruvate dehydrogenase complex and accumulation of acetylcarnitine 
prior to exercise via dichloroacetate infusion would not be effective in enhancing the rate 
of increase of oxidative metabolism during the transition to exercise at this intensity.   
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Materials and Methods 
Ethical Approval 
The study was approved by the ethical committee of the Guy’s & St Thomas’ Hospital 
Trust and all procedures were conducted in accordance with the Declaration of Helsinki. 
 
Participants 
Eight healthy and active male non-smokers (age: 33.6  2.0 yrs; mass: 74.7 ± 3.0 kg; 
2oV
 max: 3.60  0.2 l.min-1) completed the two-trial study.  Before taking part in the 
study, all participants underwent routine medical screening and completed a general 
health questionnaire. All gave their written informed consent to take part in the study and 
were aware that they were free to withdraw from the experiment at any point.  
 
Preliminary testing 
Participants performed two preliminary exercise tests and one familiarisation trial in the 2 
weeks before the first experimental trial.  A submaximal test, to determine the 
relationship between pulmonary oxygen uptake and power output, and a maximal ramp 
test, to determine 2oV
 max, were completed.  From these tests and a number of 
familiarisation trials, a workload which elicited 90% 2oV
 max after 3 min of exercise was 
calculated (301 ± 14 W), in a similar manner to the procedures of Savasi et al. (2002).   
 
Pre-experimental procedures 
Every effort was made to control factors such as diet and training status and participants 
were fully familiarised with the laboratory conditions and procedures having completed 
numerous preliminary trials.  Participants were therefore instructed to consume their 
habitual diet and refrain from strenuous physical activity, smoking and consuming 
alcohol in the 48 h prior to each trial.  Participants were also asked to record food 
consumed during the 48 h prior to the first trial and to eat the same foods during the 
same period prior to the second trial. 
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Dichloroacetate 
dichloroacetate (monosodium salt) was obtained from Sigma Aldrich and prepared 
under sterile conditions by the pharmacy at St Thomas’ Hospital (London) at a 
concentration of 25 mg
.
ml
-1
.  Participants received 50 mg
.
kg
-1 
body mass (bm) 
dichloroacetate over the 30 min infusion period, which ended 15 min before exercise. 
 
Experimental protocol 
On arrival at the laboratory (am) overnight fasted participants rested in an upright, 
seated position for ~30 min before a cannula was inserted into an antecubital vein and a 
resting blood sample obtained.  A 30 min infusion (either 0.9% saline or dichloroacetate) 
was then started, ending 15 min before the start of exercise.  Participants received a 
total volume of 2 ml
.
kg
-1
bm at an infusion rate of 4 ml
.
kg
-1 
bm
.
h
-1
.  Approximately 10 min 
before the onset of exercise, the skin and fascia over the anterior aspect of one thigh 
was anaesthetised (2-3 ml of 2% w:v lignocaine, Antigen Pharmaceuticals, Ireland) and 
two small incisions were made in skin, subcutaneous layers and fascia to allow 
extraction of muscle samples using the percutaneous needle biopsy technique with 
suction applied.  Alternate legs were used for the two trials. Immediately before exercise 
a muscle biopsy was extracted from the vastus lateralis of the leg.  Participants then 
positioned themselves on the ergometer and breathed at rest through a mouthpiece 
connected to a unit, which calculated breath-by-breath oxygen consumption 
(MedGraphics CPX/D, Minnesota, USA).  Continuous, non-invasive measurements of 
muscle deoxygenation status were made via near infrared spectroscopy measurements 
on the non-biopsied leg (see below).  Exercise commenced from rest (stationary, so as 
not to blunt the effect of dichloroacetate infusion) and consisted of cycling for 3 s at 20 
W (in order to overcome the inertia of the ergometer flywheel) and then 177 s at 
90% 2oV
 max.  It was not possible to mechanically accelerate the flywheel prior to 
exercise onset.  Immediately upon completion of exercise a second biopsy was 
extracted from the second incision while the participants were seated on the bike.  The 
participants then remained seated on the ergometer for 12 min before completing a 
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further 5 min of exercise at 100 W; after which a tourniquet was immediately inflated 
around the leg (non-biopsied leg, interrogated by near infrared spectroscopy) to 260 
mmHg for 1 min and then quickly deflated.  This allowed for collection of post-exercise 
blood samples and normalisation of the near infrared spectroscopy data to the 
physiological range – see near infrared spectroscopy.  After 14 days the participants 
repeated the above protocol, but having the other solution infused this time. 
 
Near infrared spectroscopy 
A near infrared spectrometer (NIRO-500, Hamamatsu, Japan) was used to examine 
relative changes in the muscle oxygenation status of the exercising muscle.  Two laser 
optodes were set into a custom designed holder that cut out ambient light, eliminated 
relative movement and maintained an inter-optode spacing of 40mm.  A differential path 
length factor of 4.94cm was used (Duncan et al., 1995); therefore the total path length 
(near infrared spectroscopy * differential path length factor) was set at 19.8cm.  The 
optode holder was attached to the flat portion of the subject’s vastus lateralis with tape 
and the participants’ cycling shorts pulled down over the top. Before exercise 
commenced, the subject extended the interrogated leg in a relaxed and still state to 
record a stable zero baseline at rest.  The NIRO-500 laser was set to fire twice a 
second.  Changes in the deoxygenated haemoglobin signal (Hb) received from near 
infrared spectroscopy are dependent on the balance between oxygen supply and 
utilisation in the field of near infrared spectroscopy interrogation; the application and 
release of an ischaemic tourniquet following 5 min of exercise at 100W (see above) 
produces maximum and minimum changes in Hb and allowed normalisation of the near 
infrared spectroscopy data to the physiological range (%Hb), (Marwood & Bowtell, 
2007).  To allow for individual differences and some day-to-day variability relating to the 
placement of the optodes, this procedure was conducted for each individual trial.  Since 
near infrared spectroscopy measures changes in oxy/deoxy-haemoglobin concentration 
in the volume of interrogated tissue, shifts in water from the extracellular to intracellular 
space will not affect near infrared spectroscopy measurements due to 
haemoconcentration of the blood.  However, subsequent alterations in muscle cell 
  10 
volume may increase the ratio of muscle cell to capillary volume in the area of near 
infrared spectroscopy interrogation possibly blunting the near infrared signal.  Whilst this 
effect may impact upon the absolute value attained during exercise it seems unlikely to 
affect the kinetic response. 
 
Pulmonary gas exchange 
Pulmonary gas exchange was measured breath by breath using an automated system 
(MedGraphics CPX/D).  Participants wore a nose-clip and breathed through a 
mouthpiece connected to a pneumotach (manufactured by MedGraphics).  The system 
was calibrated prior to each trial using two gases of known concentration spanning the 
range of anticipated fractional gas concentrations (low O2 / high CO2 and high O2 / zero 
CO2).  A previous study has demonstrated validity of the MedGraphics CPX/D system 
during simulated exercise testing in both normoxia and hyperoxia (Prieur et al., 1998). 
 
2oV
 & near infrared spectroscopy kinetic analysis  
Abnormal breaths due to coughs and swallows were first removed from the 2oV
 data to 
prevent skewing of the underlying response.  The criterion for removal of these breaths 
was those that were different to the mean of the adjacent four data points by more than 
three times the standard deviation of those four points.  The 2oV
  data were then 
interpolated second-by-second between 0 – 180 s.  The first 20 s of 2oV
  data were not 
included in the fitting processes.  From 21 s onward, the data were fitted to a mono-
exponential curve with a delay relative to the onset of exercise of the forms: 
)1(* 221
2
/)(
1)0(2)(2
VoVoTDt
Vot eAoVoV


  
Where 
)0(2
oV  is the pulmonary oxygen consumption measured at the onset of exercise 
(Rossiter et al., 1999), 
21Vo
A  is the asymptotic amplitude of the phase II response, 
2Vo
  
is the time constant for the phase II component of the response and 
21Vo
TD  is a time 
delay similar, but not equal to the phase I – phase II transition time (Rossiter et al. 
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1999).  The absolute oxygen uptake of the phase II (fundamental) component of the 
response (
)2(2 
oV ) is therefore the sum of 
)0(2
oV  and 
21Vo
A .  The fitting strategy was 
designed to identify the onset of the “slow component” of the response to exercise 
(
22Vo
TD ).  Using custom written software and the “Solver” function in Microsoft Excel, 
the fitting window was widened by 1 s intervals from 60 s until the end of exercise with 
the time constant of the curve of best fit for each time window plotted against time 
(Marwood & Bowtell 2007).  The goodness of fit was determined by the maintenance of 
a flat profile for the residual plot and minimisation of the sum of the error squared data 
(Solver, Microsoft Excel).  The onset of the slow component could then be identified as 
the point at which a plateau in the value of  was followed by a progressive increase, as 
its value becomes affected by the slow component (Marwood & Bowtell 2007).  The time 
at which this occurred was used as the optimal fitting window with which to estimate the 
kinetics of the phase II component.  The amplitude of the slow component (
22Vo
A ) was 
calculated as the difference between this and the mean 2oV
  during the final 30 s of 
exercise ( 2oV

(180-150s)).  To provide an indication of the overall kinetic response to 
exercise, the mean response time (
2VO
MRT ) was calculated as TD1 + .  Total oxygen 
uptake during exercise was calculated via integration of the 2oV
  - time curve and 
estimated accumulated oxygen deficit was calculated as this value minus ( 2oV

(180-150s) * 
3 min). 
 
Near infrared spectroscopy kinetic analysis  
%Hb kinetics were analysed in a similar manner to 2oV
 kinetics.  Data prior to the 
minimum points which occurred shortly after the onset of exercise (%Hbmin, see figure 4) 
were removed from the dataset.  Although it is not certain whether the processes 
underlying the %Hb  response are exponential in nature, visual inspection of the data 
and reference to previous literature (DeLorey, Kowalchuk, & Paterson, 2005) suggests 
that a monoexponential decay model of the form below provides a reasonable estimate 
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of the time course of muscle deoxygenation during the “primary” phase of the %Hb 
response: 
 
)1(*%)(% %%1
/)(
%min
HbHbTDt
Hb eAHbtHb
  
 
TD1%Hb is the time delay (relative to the start of exercise) of this “primary” component of 
%Hb and is derived during the fitting process, whereas A%Hb and %Hb are the amplitude 
and the time constant of this response.  The overall amplitude of this “primary” response 
of %Hb (%Hbp) is therefore the sum of %Hbmin and A%Hb.   
 
By implication of the model used, a plateau occured in the %Hb data.  However, similar 
to 2oV
  kinetics during heavy and very heavy exercise intensities, this plateau was only 
transient.  Hence the fitting strategy utilised was similar to that for 2oV
  kinetics whereby 
an iterative process aids determination of the optimum fitting window for the “primary” 
response of %Hb kinetics.  Specifically, utilising the same routines, the fitting window 
was widened by 0.5 s intervals from 30 s until the end of exercise with the time constant 
of the curve of best fit for each time window plotted against time; identification of the 
optimum window for fitting %Hb kinetics and the goodness of fit determined as for 2oV
  
kinetics.  The degree of drift in the %Hb data from the “primary” %Hb  response to end 
exercise (A2%Hb, akin to a “slow component” of %Hb) was calculated as the difference 
relative to the final 30 s of exercise (%Hb180-150s).  To give an indication of the overall 
kinetic response to exercise, the mean response time (MRT%Hb) was calculated as TD1 + 
. 
 
Blood analysis   
Venous blood samples were taken at rest (-45 min), immediately post infusion (-15 min), 
immediately prior to exercise (0 min) and 3, 6 and 12 min following the termination of 
exercise (6, 9, 15 min respectively).  Venous blood samples were immediately 
centrifuged at 13,000 rpm for 2 min, the supernatant collected, snap frozen in liquid 
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nitrogen and stored at -80C.  Plasma samples were later analysed for lactate 
concentration by an automated colorimetric assay (Cobas Mira). 
 
Muscle analysis 
After extraction, muscle samples were immediately immersed in liquid nitrogen, removed 
from the needle while muscle still frozen and stored in liquid nitrogen until freeze dried 
and stored at -80ºC.  All samples were divided into two pieces under liquid nitrogen.  
One portion was freeze dried, dissected free of visible blood and connective tissue, 
powdered and washed twice with petroleum ether to remove any fat.  Aliquots of the 
powdered muscle were extracted with 0.5 M perchloric acid (containing 1 mM EDTA), 
and after centrifugation, the supernatant was neutralized with 2.1 M KHCO3.  Extracts 
were assayed enzymatically for lactate, adenosine triphosphate, adenosine 
diphosphate, phosphocreatine and creatine using a fluorometer (Hitachi F2000 
fluorescence spectrophotometer, Hitachi Instruments, Japan) and for acetylcarnitine and 
free carnitine by enzymatic assays that made use of radioisotopic substrate (Cederblad, 
Carlin, Constantin-Teodosiu, Harper, & Hultman, 1990).  Intramuscular metabolite 
contents (adenosine triphosphate, phosphocreatine, creatine) were normalised for each 
individual’s highest total creatine content across each of the four samples.  The non-
oxidative adenosine triphosphate provision or substrate level phosphorylation was 
calculated as 2 * [ adenosine triphosphate] + 1.5 * [Lactate] + [ phosphocreatine].  
The remaining portion of frozen wet muscle was used to assess pyruvate 
dehydrogenase complex activation (Constantin-Teodosiu, Cederblad, & Hultman, 1991) 
with a correction made for total alkaline protein content (Sahlin, Katz, & Broberg, 1990). 
 
Statistics   
All values are presented as mean ± standard deviation with an n of 8, unless otherwise 
indicated.  Normality of distribution of all datasets was confirmed via one sample 
Shapiro-Wilk normality tests.  Time course dependent data were analysed by a two way 
ANOVA for repeated measures {treatment (dichloroacetate vs saline) by time}.  The 
specific location of any effect was identified using a pairwise analysis (t-test) corrected 
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by a Sidak-based Holm step-down procedure for multiple comparisons.  All other data 
were analysed by a two-tailed paired t-test.  Significance was set at the P<0.05 level of 
confidence. 
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Results 
Pyruvate dehydrogenase complex activation 
Both at rest and after exercise, pyruvate dehydrogenase complex activity was 
significantly higher following dichloroacetate infusion compared to control (P=0.01) and 
exercise resulted in a significant increase in pyruvate dehydrogenase complex activity in 
control only (P=0.001).  There was no significant difference in pyruvate dehydrogenase 
complex activity between trials following exercise, {pre-ex: 2.7 ± 2.2 (control) vs 17.9 ± 
2.4 (dichloroacetate); post-ex: 11.9 ± 4.9 (control) vs 17.2 ± 3.0 (dichloroacetate) mmol 
acetyl-CoA min
-1.
mg
-1 
protein, Fig 1}.  Post-exercise muscle pyruvate dehydrogenase 
complex activity data are available for only 5 participants due to the extraction of 
insufficient muscle.   
 
Muscle metabolites 
Muscle adenosine triphosphate, phosphocreatine, lactate, creatine and total creatine 
concentrations were unaffected by dichloroacetate infusion compared to saline at rest or 
following exercise (Table 1).  Substrate level phosphorylation was also not different 
following dichloroacetate infusion compared to saline {125 ± 57 (control) vs 113 ± 35 
(dichloroacetate) mmol adenosine triphosphate
.
kg
-1
dm}. 
 
Muscle acetylcarnitine concentration was significantly higher following dichloroacetate 
infusion compared to saline both prior to and after exercise; and significantly higher 
post-exercise compared to pre-exercise in both trials, (main effect time, P<0.001; main 
effect dichloroacetate, P=0.006; Fig. 2).  The percentage increase in acetylcarnitine from 
rest to exercise was significantly higher following saline infusion compared to 
dichloroacetate {480 ± 393 (control) vs 114 ± 51 (dichloroacetate) %, main effect 
dichloroacetate, P=0.03, Fig. 2}, but the absolute increase in acetylcarnitine content 
from pre-exercise to post-exercise was not different between conditions {8.3 ± 4.1 
(control) vs 8.3 ± 3.0 (dichloroacetate) mmol
.
kg
-1
dm}.  Muscle free carnitine 
concentration showed the inverse of these effects.  Total muscle carnitine concentration 
was unchanged by exercise or dichloroacetate infusion {pre-ex: 23.2 ± 3.3 (control) vs 
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21.2 ± 4.3 (dichloroacetate) mmol
.
kg
-1
dm; post-ex: 21.1 ± 4.0 (control) vs 21.8 ± 3.9 
(dichloroacetate) mmol
.
kg
-1
dm}. 
 
Pulmonary gas exchange 
The time constant of the phase II kinetics of pulmonary oxygen uptake was not different 
between trials (Table 2).  However, 
2VO
MRT was greater following dichloroacetate 
infusion compared to control (P=0.04, Table 2}.  In contrast, total oxygen consumption 
{7.95 ± 0.28 (control) vs 7.64 ± 0.29 (dichloroacetate) litres O2} and estimated 
accumulated oxygen deficit {1.85 ± 0.23 (control) vs 1.77 ± 0.13 (dichloroacetate) litres 
O2} were unchanged between trials (P=0.5, P=0.4, respectively).  The onset of the slow 
component of oxygen consumption was also greater following dichloroacetate infusion 
compared to control (P=0.05, Table 2}. There was also a tendency for the absolute 
amplitude of the fundamental response (phase III) to be higher following dichloroacetate 
infusion (P=0.09) with a concomitant tendency for the amplitude of the slow component 
to be lower (P=0.07, Table 2).  The average 95% confidence interval of the fitted time-
constant parameter 
2Vo
  was 4.3 ± 0.8 and 3.1 ± 0.3) s in control and dichloroacetate 
trials, respectively.  Figure 3 shows representative plots for control and dichloroacetate 
trials with the phase II kinetic curves and residual plots shown.  End-exercise oxygen 
consumption represented 90.3 and 88.0 % 2oV
 max for the control and dichloroacetate 
trials respectively (P=0.3). 
 
Near infrared spectroscopy 
The time constant of the kinetics of %Hb was greater following dichloroacetate infusion 
compared to control (P=0.004, Table 3).  Furthermore, TD%Hbmin was also significantly 
greater following dichloroacetate infusion compared to control (P=0.04, Table 3).  
Consequently, MRT%Hb was also greater following dichloroacetate infusion (P=0.003, 
Table 3).  The average 95% confidence interval of the fitted parameter %Hb was 0.4(0.1) 
and 0.5(0.1) s for the control and dichloroacetate trials respectively.  Figure 4 shows 
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representative plots for control and dichloroacetate trials with the “primary” component 
kinetic curves and residual plots shown. 
 
Plasma metabolites 
Plasma lactate concentration was unchanged between trials; the post-exercise rise in 
plasma lactate concentration (measured 3 min following the termination of exercise) was 
also not different between trials {control: 5.9 ± 2.5 vs dichloroacetate: 6.6 ± 2.8 mmol
.
l
-1
, 
n.s.; Fig. 5}.  
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Discussion 
The present investigation clearly demonstrates that prior dichloroacetate infusion, which 
resulted in activation of the pyruvate dehydrogenase complex and accumulation of 
acetyl groups had no effect on non-oxidative adenosine triphosphate provision following 
3 min of cycle exercise at 90% 2oV
 max.  Secondly, and in line with the metabolic 
findings, prior dichloroacetate infusion had no effect on the time constant of phase II 
pulmonary oxygen kinetics during subsequent severe intensity exercise. 
 
Hochachka & Matheson (Hochachka & Matheson 1992) and recent theoretical studies 
(Korzeniewski & Zoladz 2004) suggest that direct activation of key enzymes in the 
oxidative respiratory chain (in addition to the stimulus provided by the rise in [adenosine 
diphosphate]) are required to adequately explain the time course of phosphocreatine, 
adenosine diphosphate and muscle oxygen consumption at the onset of exercise.  In 
this regard, a large body of evidence suggests that a lag in pyruvate dehydrogenase 
complex activation and flux determines a significant proportion of the “metabolic inertia” 
inherent within skeletal muscle at the onset of exercise (Timmons et al. 1998a; Roberts 
et al. 2002; Greenhaff et al. 2002).  Consequently, pyruvate dehydrogenase complex 
activation and stockpiling of acetyl groups in resting muscle prior to contraction via 
dichloroacetate infusion has been shown to reduce inertia in oxidative adenosine 
triphosphate provision at the onset of subsequent contraction (Roberts et al. 2002; 
Greenhaff et al. 2002).  However, Roberts et al. (Roberts et al. 2002) suggested that the 
acetyl group deficit exists only within a finite range of exercise intensities, i.e. ~ 65–
90% 2oV
 max, outside of which the non-oxidative adenosine triphosphate provision will 
not be reduced by increasing resting acetyl group availability.  The present data support 
the hypothesis of Roberts et al. (Roberts et al. 2002) that 90% of 2oV
 max is an upper 
limit to the range at which the acetyl group deficit exists.  The present data bear 
similarity with previous studies (Savasi et al. 2002) that demonstrated no effect of 
dichloroacetate infusion on non-oxidative adenosine triphosphate provision following the 
transition to exercise at 110% max leg-kicking capacity (Bangsbo et al. 2002) and cycle 
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exercise at 90% 2oV
 max (Savasi et al. 2002). Conversely, the present data seem to be 
at odds with a recent paper (Timmons et al. 2004) where following dichloroacetate 
infusion phosphocreatine degradation in canine skeletal muscle was lower in the first 
minute of intense tetanic stimulation compared to control.  However, aside from the 
obvious muscle fibre type difference, it is likely that these two datasets arise from distinct 
exercise intensity domains.  A meta-analysis conducted by Timmons et al. (Timmons et 
al. 2004) suggested that an ‘acetyl group deficit’ exists only when the average rate of 
phosphocreatine degradation during the first minute of exercise is less than 1 mmol kg 
dm
-1
 s
-1
, as was the case in the study by Timmons et al.  2004.  Due to the timing of 
muscle samples in the present study (i.e. 3 min apart) it is not possible to accurately 
evaluate the initial phosphocreatine utilisation rate.  However, the exercise intensity 
utilised in the present study has previously been demonstrated to result in an initial 
phosphocreatine utilisation rate > 1 mmol kg dm
-1
 s
-1
 (~ 1.2 mmol kg dm
-1
 s
-1
) (Savasi et 
al. 2002).  Given the negligible change in phosphocreatine from 2 min of exercise 
onwards even during moderate intensity exercise (Howlett et al. 1999), the reduction of 
phosphocreatine by ~ 45 mmol kg dm
-1
 during 3 min exercise in the present study is line 
with the data of Savasi et al. (Savasi et al. 2002) who demonstrated a reduction of ~ 43 
mmol kg dm
-1
 across the total 90 s exercise period. Hence we are confident that the 
initial phosphocreatine utilisation rate was greater than the target level 1 mmol kg dm
-1
 s
-
1
. 
 
A reasonable explanation for the lack of any beneficial effect of priming the muscle with 
acetyl groups prior to high intensity exercise could be as follows.  The magnitude of 
pyruvate dehydrogenase complex activation is central to the control of acetyl-CoA 
delivery to the tricarboxylic acid cycle and carbohydrate oxidation
 
in contracting skeletal 
muscle.  As such, pyruvate dehydrogenase complex activity
 
increases, from its relatively 
low activation status at rest,
 
in parallel with exercise intensity up to an intensity of 
90% 2oV
 max as the rate of carbohydrate oxidation becomes maximal (Constantin-
Teodosiu, Carlin, Cederblad, Harris, & Hultman, 1991; Howlett et al., 1998).  This would 
suggest that there is an upper workload intensity above which the rate of acetyl group 
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delivery is no longer limiting towards tricarboxylic acid cycle demand since (i) above this 
exercise intensity the pyruvate dehydrogenase complex is working maximally and (ii) 
any further gains in aerobic contribution would become disproportionately insignificant 
when reported relative to the total energy requirement.  
 
In the present study, dichloroacetate infusion resulted in a significant enhancement of 
pre-exercise pyruvate dehydrogenase complex activation relative to control (2.7 vs 17.9 
nmol acetyl-CoA min
-1.
mg
-1
 protein), resulting in a several fold accumulation of 
acetylcarnitine prior to exercise (relative to control).  However, despite this increased 
acetyl group availability accumulation of acetylcarnitine continued during the transition 
from rest to exercise following dichloroacetate infusion, a phenomenon not associated 
with those exercise intensities demonstrating an acetyl group deficit, (Timmons et al. 
1996; Timmons, Poucher, Constantin-Teodosiu, Macdonald, & Greenhaff, 1998; 
Timmons et al. 1998a; Howlett et al. 1999; Roberts et al. 2002; Timmons et al. 2004). 
This suggests that a further limitation exists downstream of the pyruvate dehydrogenase 
complex reaction during the transition to exercise at this intensity.  
 
Pulmonary oxygen uptake & muscle deoxygenation kinetics 
Speeding of pulmonary oxygen uptake kinetics can be considered indicative of an 
increased rate of muscle oxygen consumption as the time constant of pulmonary 2oV
  
kinetics is suggested to be a proxy for muscle oxygen consumption kinetics (Rossiter et 
al. 1999).  To improve the signal-to-noise ratio of breath-by-breath pulmonary 
2oV
 measurements multiple exercise transitions are often utilised and ensemble 
averaged.  This reduces the 95% confidence interval (CI) of the estimation of 
2Vo
 during 
calculation of pulmonary 2oV
  kinetics (Lamarra, Whipp, Ward, & Wasserman, 1987; 
Fawkner, Armstrong, Potter, & Welsman, 2002).  Unfortunately due to ethical committee 
concerns over the infusate, we were unable to conduct more than one exercise 
transition.  However, despite the use of only a single transition for each condition in the 
present study, the large amplitude of the pulmonary 2oV
  and the familiarisation of the 
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participants with breathing through a mouthpiece resulted in average 95% CI for 
2Vo
 of 
4.3 ± 0.8 and 3.1 ± 0.3 s for the CON and dichloroacetate trials, respectively.  Fawkner 
et al (Fawkner et al. 2002) suggested that 95% CI of ±5 for 
2Vo
   is an appropriate 
target.  Hence the 
2Vo
 data provide support for the muscle metabolite data, 
demonstrating no effect of dichloroacetate infusion prior to exercise at 90% 2oV
 max.   
 
In contrast to muscle metabolite and 
2Vo
  data, the mean response time of pulmonary 
oxygen uptake kinetics was slower following dichloroacetate infusion, one interpretation 
of which being that the rate of increase of oxidative metabolism was slower following 
dichloroacetate infusion.  However, given the biopsy and 
2Vo
 data from the present 
study, and the finding of no difference in either estimated accumulated oxygen deficit or 
total oxygen uptake, this appears unlikely. The greater mean response time following 
dichloroacetate infusion appears to be primarily due to the tendency for a greater time 
delay of the phase I – phase II transition point of the fundamental component (P=0.1).  
Little physiological meaning has generally been attributed to this time-delay. In the face 
of no alteration in a number of parameters indicative of oxidative metabolism, the weight 
of the available evidence would suggest that dichloroacetate had no effect on the rate of 
increase of oxidative metabolism at the present exercise intensity. 
 
The slow component of oxygen uptake is characterised by an additional oxygen uptake 
in excess of the phase II (fundamental) component which is typically presented ~ 90 – 
180 s following the onset of exercise above the lactate threshold.  In the present and a 
previous (24) study, the onset of the slow component was delayed following 
dichloroacetate infusion (111 vs 141 s). In the present study, this was associated with a 
blunting of the amplitude of the slow component as expressed after 3 min of exercise 
(P=0.07) as also demonstrated by Rossiter et al. (Rossiter et al. 2003).  However in 
contrast to Rossiter et al (Rossiter et al. 2003), we also found tendencies for an increase 
in the absolute value of the fundamental component (i.e. phase III, P=0.09) in the 
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present study. There was no difference between trials in the end-exercise oxygen 
uptake.  Taken together, these effects of dichloroacetate infusion on pulmonary oxygen 
uptake kinetics (no effect on the phase II time constant, blunted slow component and 
enhancement of the absolute value of the fundamental amplitude) are similar to that 
demonstrated by priming exercise (for review see Jones et al.  2003, (Jones, Koppo, & 
Burnley, 2003)).  Priming exercise may exert its effect on subsequent exercise via a 
number of potential mechanisms.  However the primary candidates would appear to be 
improvements in oxygen availability to the exercising muscle (via enhanced convection 
and diffusion, (Jones, Berger, Wilkerson, & Roberts, 2006) and increases in muscle fibre 
recruitment in all fibre types, (Burnley, Doust, Ball, & Jones, 2002). 
 
Although, an enhancement in muscle fibre recruitment might best explain the tendency 
for the absolute amplitude of the fundamental component of pulmonary oxygen uptake 
kinetics to be higher following dichloroacetate infusion there is certainly no direct 
evidence to suggest that dichloroacetate has the capacity to alter muscle fibre 
recruitment.  On the other hand, some (Macdonald, Pedersen, & Hughson, 1997), but 
not all (Wilkerson, Berger, & Jones, 2006) studies have encountered a similar 
phenomenon during exercise in hyperoxia where oxygen delivery is presumably 
enhanced.  Therefore, evidence for an effect of dichloroacetate on oxygen delivery 
although debatable has thus far been based on inferences from pulmonary oxygen 
uptake kinetics during high intensity exercise (Rossiter et al. 2003; Jones et al. 2004) 
and present study.  Nevertheless, the near infrared spectroscopy data from the present 
study provide further evidence that the above described effects of dichloroacetate 
infusion on pulmonary oxygen uptake kinetics occurred via an enhancement of oxygen 
delivery to the exercising muscle although the mechanism is unclear. 
 
No previous study has utilised interrogation of exercising human muscle via near 
infrared spectroscopy following dichloroacetate infusion.  Given previous data (Howlett & 
Hogan 2003) where dichloroacetate administration resulted in a faster rate of decrease 
in intracellular oxygen pressure at the onset of contractions in single, isolated muscle 
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fibres, one might have expected that the kinetics of %Hb during the transition from rest 
to exercise would be faster following dichloroacetate infusion.  Alternatively, given the 
absence of any effect of dichloroacetate infusion on non-oxidative adenosine 
triphosphate provision in the present study, one might predict that dichloroacetate 
infusion would have no effect on %Hb kinetics.  Therefore, the finding of slower %Hb 
kinetics (time constant and mean response time) during the transition from rest to 
exercise was unexpected.  Slower %Hb kinetics are indicative of a slower rate of 
increase of fractional oxygen extraction by the muscle.  This could be due to either (i) a 
slower rate of increase of oxidative or mitochondrial adenosine triphosphate provision or 
(ii) enhanced oxygen delivery throughout the exercise transition.  The former possibility 
can be excluded on the basis of equivalent non-oxidative adenosine triphosphate 
provision in both trials.  Therefore, it appears that dichloroacetate infusion could have 
promoted enhanced oxygen delivery in the exercising muscle such that the rate of 
increase of deoxygenation of the muscle microvasculature was slowed.  Additionally, the 
amplitude of the drift in %Hb (similar to the slow component of pulmonary oxygen 
uptake) was also blunted by dichloroacetate infusion which is similar to that previously 
demonstrated in hyperoxia (Marwood & Bowtell 2007) further supporting the notion that 
oxygen delivery was enhanced.  So far, there is little direct evidence available to support 
the idea that dichloroacetate enhances muscle oxygen delivery.  However, it has been 
shown that oxygen delivery to canine hypoxic skeletal muscle was enhanced following 
dichloroacetate infusion (Graf, Leach, & Arieff, 1985).  Furthermore, when human 
volunteers were given the same amount of dichloroacetate to the present study (50 
mg
.
kg
-1
) in a single bolus, there was a significant decrease in peripheral resistance and 
a concomitant improvement in oxygen availability (Ludvik, Peer, Berzlanovich, Stifter, & 
Graf, 1991). The precise mechanism(s) behind these effects are not clear, but it has 
been suggested (Graf et al. 1985) that it could involve the binding of oxygen to 
haemoglobin. Whether this is related to an increase in haemoglobin oxygen saturation, 
an enhanced unloading of oxygen at the site of gas exchange or an interaction with nitric 
oxide release (reduced peripheral resistance and thus enhanced blood flow) is as yet 
unclear. 
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A large number of studies have demonstrated a reduction in non-oxidative adenosine 
triphosphate provision during the transition from rest to exercise following 
dichloroacetate infusion (Durkot et al. 1995; Timmons et al. 1996; Timmons et al. 1997; 
Timmons et al. 1998a; Timmons et al. 1998b; Howlett et al. 1999; Parolin et al. 2000; 
Roberts et al. 2002; Howlett & Hogan 2003).  The mechanism by which dichloroacetate 
exerts this effect has been shown to be via activation of the pyruvate dehydrogenase 
complex and resultant reduction in the acetyl group deficit (Durkot et al. 1995; Timmons 
et al. 1996; Timmons et al. 1997; Timmons et al. 1998a; Timmons et al. 1998b; Howlett 
et al. 1999; Parolin et al. 2000; Roberts et al. 2002; Howlett & Hogan 2003).  However 
given the present 2oV
  and %Hb kinetic data, the effects of prior dichloroacetate infusion 
on muscle metabolism at these lower exercise intensities (relative to the present study) 
may also in part be due to improvements in muscle oxygen delivery.  In other words, 
improvements in oxygen delivery via dichloroacetate infusion may act in combination 
with the reduction in the acetyl group deficit and enhancement of pyruvate 
dehydrogenase complex activation to achieve the reduced reliance on non-oxidative 
adenosine triphosphate provision during subsequent moderate intensity exercise.  Such 
an effect would however need to be confirmed in future studies.   
 
The present study investigated the effect of prior dichloroacetate infusion on oxidative 
metabolism during subsequent exercise at 90% 2oV
 max.  In contrast to some previous 
studies, the expected effects of dichloroacetate on pyruvate dehydrogenase complex 
activity and acetylcarnitine accumulation were directly assessed, and we utilised a 
combination of both invasive (muscle metabolite analysis) and non-invasive (pulmonary 
oxygen uptake and muscle deoxygenation kinetics)
 
methods to evaluate the effect of 
dichloroacetate on oxidative metabolism.  The results clearly demonstrate that despite 
the accumulation of muscle acetyl groups and activation of the pyruvate dehydrogenase 
complex induced by dichloroacetate, non-oxidative adenosine triphosphate provision 
during a 3 min bout of exercise at 90% 2oV
 max was not affected.  Secondly, and in line 
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with the metabolic findings, the present study also demonstrated that prior 
dichloroacetate infusion had no effect on the phase II time component of pulmonary 
oxygen uptake.  This absence of acetyl group deficit at the onset of exercise at 
90% 2oV
 max, suggests an upper limit to the exercise intensity range at which the acetyl 
group deficit occurs beyond which further downstream limitations may be present.  Other 
novel findings of the present study were that muscle deoxygenation kinetics were 
slowed and the slow component of pulmonary oxygen consumption and muscle 
deoxygenation was blunted following dichloroacetate infusion, indicating that 
dichloroacetate infusion enhanced oxygen delivery to the exercising muscle.  The 
significance of these latter findings may be that prior infusion of dichloroacetate exerts 
its beneficial effects on non-oxidative adenosine triphosphate provision during moderate 
intensity exercise via a combination of reduction in the acetyl group deficit, activation of 
pyruvate dehydrogenase complex and an improvement in oxygen delivery. 
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Tables 
 
Table 1  Muscle adenosine triphosphate (ATP), phosphocreatine  (PCr), lactate, 
glycogen, creatine (Cr) and total creatine (TCr) concentrations before and after 3 min 
bout of exercise at 90% 2oV
 max, following i.v. infusion of 0.9% saline (CON) or 
dichloroacetate (DCA) 
 CON DCA 
 Pre-ex Post-ex  Pre-ex Post-ex 
ATP 25.0 ± 2.2 22.4 ± 3.2 -2.6 ± 3.3 24.1 ± 4.0 25.4 ± 9.1 1.3 ± 6.5 
PCr* 77.2 ± 8.4 33 ± 13 -45 ± 18 72 ± 15 29.3 ± 8.0 -42.9 ± 7.0 
Lactate* 3.2 ± 1.0 53 ± 30 50 ± 30 2.5 ± 0.7 51 ± 20 48 ± 20 
Cr* 45 ± 11 99 ± 15  53 ± 21 46 ± 13 82 ± 26 36 ± 27 
TCr 132 ± 11 136 ± 15 5 ± 15 130 ± 19 125 ± 16 5 ± 14 
Values represent means ± SD and are expressed as mmolkg
-1
 dry muscle (n=8). 
change from pre-exercise to post-exercise; *Time main effect from pre-exercise to 
post-exercise within treatment groups (P<0.001). 
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Table 2  Pulmonary oxygen consumption parameters during a 3 min bout of exercise at 
90% 2oV
 max, following i.v. infusion of 0.9% saline (CON) or dichloroacetate (DCA) 
 
 CON DCA 
VO2(b) (l.min
-1
) 0.52 ± 0.03 0.48 ± 0.03 
VO2(0) (l.min
-1
) 1.12 ± 0.31 0.82 ± 0.42 
A1VO2 (l.min
-1
) 1.89 ± 0.25 2.20 ± 0.40 
VO2(ss) (l.min
-1
) 3.0 ± 1.4 3.0 ± 1.1 
TD1VO2 (s)* 4 ± 11 16.7 ± 3.7 
1VO2 (s) 21.3 ± 5.4 22.9 ± 6.2 
MRTVO2 (s)*
 
25.4 ± 8.5 39.6 ± 6.2 
TD2VO2 (s)* 113 ± 25 151 ± 31 
A2VO2 (l.min
-1
) 0.25 ± 0.14 0.12 ± 0.20 
 
Values represent mean ± SD (n=8).  *Treatment (DCA infusion) main effect (P<0.05).  
)0(2oV

: oxygen uptake at the onset of exercise; 
21Vo
A : asymptotic amplitude of the 
phase II response )2(2 oV

:  absolute value of fundamental response; 
21Vo
TD : time 
delay (relative to the onset of exercise) similar but not equal to the phase I – phase II 
transition; 
2Vo
 : time constant of the phase II response; 
2VO
MRT : mean response time 
of phase II;  
22Vo
TD : time delay of the slow component; 
22Vo
A : amplitude of the slow 
component; )150180(2 ssoV 

: mean oxygen uptake during the last 30 s of exercise 
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Table 3  Summary of the %Hb kinetic parameters during a 3 min bout of exercise at 90% 
2oV
 max, following i.v. infusion of 0.9% saline (CON) or dichloroacetate (DCA) 
 
 CON DCA 
%Hbmin 10.7 ±  8.1 7.9 ± 5.9 
A%Hb 57 ± 11 64 ± 11 
%Hb(ss)
 
68 ± 12 72 ± 11 
%Hb(150-180) 75 ± 12 76 ± 11 
TD%Hbmin (s)* 4.6 ± 1.4 6.2 ± 1.9 
TD%Hb (s) 4.5 ± 1.4 6.4 ± 2.7 
%Hb (s)* 6.6 ± 3.1 9.7 ± 1.9 
MRT%Hb (s)* 11.4 ± 2.7 17.5 ± 2.7 
TD2%Hb (s) 100 ± 33 102 ± 47 
A2%Hb* 7.2 ± 5.7 3.5 ± 4.3 
Table 3. Values that represent mean ± SD (n=8).  *Treatment (DCA infusion) main effect 
(P<0.05).  %Hbmin: minimum point achieved shortly after onset of exercise; A%Hb: 
amplitude of the “phase II” (primary) response; %Hb(ss): absolute value of the “phase II” 
(primary) response; TD%Hbmin: time delay of %Hbmin; TD1%Hb: time delay of the “phase II” 
(primary) response (derived during the fitting process); %Hb: time constant of the “phase 
II” (primary) response; MRT%Hb: mean response time;  TD2%Hb: time delay of the “slow 
component”; A2%Hb: amplitude of the “slow component”; %Hb(180-150s): mean during the 
final 30 s of exercise. 
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Figure legends 
 
Figure 1.  Muscle pyruvate dehydrogenase complex activation (PDCa) before and after 
a 3 min bout of exercise at 90% 2oV
 max following i.v. infusion of 0.9% saline (CON) or 
dichloroacetate (DCA).  Values are expressed as nmol acetyl-CoA min
-1
 mg
-1
 protein 
(n=5). *Significantly different to resting value (pairwise analysis, P<0.05); 
$
Significantly 
different to CON (pairwise analysis, P<0.05). 
 
Figure 2.  Muscle acetylcarnitine concentration before and after a 3 min bout of exercise 
at 90% 2oV
 max following i.v. infusion of 0.9% saline (CON) or dichloroacetate (DCA). 
There was a main effect of time (P<0.001) and of DCA infusion (P<0.01).  *Significantly 
different to resting value (pairwise analysis, P<0.05); 
$
Significantly different to CON 
(pairwise analysis, P<0.05). 
 
Figure 3.  Representative plots for pulmonary 2oV
  kinetics for CON (open squares) and 
DCA (closed squares) with the phase II kinetics curve and residuals shown. 
 
Figure 4.  Representative plots for pulmonary %Hb kinetics for CON (open squares) and 
DCA (closed squares) with the phase II kinetics curve and residuals shown. 
 
Figure 5.  Plasma lactate concentration before and after a 3 min bout of exercise at 90% 
2oV
 max following i.v. infusion of 0.9% saline (CON) or dichloroacetate (DCA).  
*Significantly different to resting values (pairwise analysis, P<0.05). 
  
 
 
 
 
